Top 12 report 2014: for the first time, the return rate of pharmaceutical R & D ushered in a turning point

Source: Biovalley December 11, 2014 Deloitte, one of the four largest accounting firms in the world, recently released a report on the top 12 pharmaceutical giants in the world since 2010 The R & D investment and return since, including Pfizer, Roche, Novartis, Sanofi, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Merck, Lilly, Bristol Myers Squibb, Takeda and Amgen, have been statistically analyzed According to the report, since 2010, the world's top 12 giants have launched 143 products, with expected lifetime income of $955 billion During the same period, 236 assets were advanced to the later stage of development, with expected lifetime income of $1171 billion From 2010 to 2013, the rate of return on drug research and development (R & D) fell all the way, but it rose for the first time in 2014, from 5.1% in 2013 to 5.5% in 2014 Although the change is not big, the rise is still welcome after three years of continuous decline Analysts point out that there are signs that the rate of return on pharmaceutical research and development is turning; however, the cost of developing a new drug continues to rise, reaching $1401 million in 2014 In addition, despite the emergence of winners, the economic drivers of product development are very complex When it comes to each company, the changes are very big Behind the 5.5% figure, there are actually huge changes However, the report did not publicly name the winners and losers of 2014 The report points out that the following strategic factors may have an impact on R & D benefits: company size - the larger the company is, the higher the cost of developing each asset, the lower the return; external innovation - for most (75%) companies, less than half of the expected revenue comes from compounds found within the enterprise For all 12 giants, 58% of the expected revenue generated from innovation in the late development stage comes from external sources Investment focus - the less treatment areas the R & D pipeline focuses on, the higher the return seems to be Neil lesser, head of Deloitte's life science R & D strategy, pointed out that the R & D ecosystem in the pharmaceutical field is undergoing a transformation, and industry giants must carefully evaluate how to obtain, cultivate and commercialize innovation results We have found that some of the top 12 pharmaceutical companies do better than others, and are reaping greater returns At present, most of the industry value is coming from external innovation, and these external assets are showing high future expectations Companies need to consider whether they have made more effective investments in talent, processes, infrastructure and data, so as to make companies more capable of successful and productive cooperation in the long run without damaging the benefits.